p38 MAPK inhibition modulates rabbit nucleus pulposus cell response to IL-1

Journal of Orthopaedic Research

Volumn 26, Issue 7, 2008, Pages 991-998

  Studer, Rebecca K ^a,b   Gilbertson, Lars G ^c   Georgescu, Helga ^b   Sowa, Gwendolyn ^b   Vo, Nam ^b   Kang, James D ^b  

^a VAPHS 151 U 2W 144 ^*  (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Disc degeneration; IL 1; Nucleus pulposus cells; p38 MAPK; Signal transduction

Indexed keywords

AGGRECAN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; INTERLEUKIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEOGLYCAN; RNA; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA; VERSICAN; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4-(4-FLUOROPHENYL)-2-(4-HYDROXYPHENYL)-5-(4-PYRIDYL)IMIDAZOLE; CYTOKINE; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CATABOLISM; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; INFLAMMATION; INTERVERTEBRAL DISK; INTERVERTEBRAL DISK DEGENERATION; NONHUMAN; NUCLEUS POLPOSUS; PAIN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY; RABBIT; SIGNAL TRANSDUCTION; SPINE DISEASE;

ANIMALS; CELLS, CULTURED; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; GENE EXPRESSION; IMIDAZOLES; INTERLEUKIN-1; INTERVERTEBRAL DISK; NITRIC OXIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEOGLYCANS; PYRIDINES; RABBITS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPINAL DISEASES;

EID: 46449096413     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20604     Document Type: Article

References (48)

1. Luo X, Pietrobon R, Sun SX, et al. 2004. Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine 29:79-86.
2. Borenstein D. 1992. Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain. Curr Opin Rheumatol 4:226-232.
3. Sabajima S, Kompel J, Kim J, et al. 2004. A slowly progressive and reproducible animal model of intervertebral disc degeneration characterized by MRI, X-Ray, and histology. Spine 30:15-24.
4. Sobajima S, Shimer AL, Chadderdon RC, et al. 2005. Quantitative analysis of gene expression in a rabbit model of intervertebral disc degeneration by real-time polymerase chain reaction. Spine J 5:14-23.
5. Roberts S, Butler RC. 2005. Inflammatory mediators as potential therapeutic targets in the spine. Curr Drug Targets Inflamm Allergy 4:257-266.
6. Wang Y-J, Shi Q, Lu WW, et al. 2006. Cervical intervertebral disc degeneration induced by unbalanced dynamic and static forces: a novel in vivo rat model. Spine 31:1532-1538.
7. Chubinskaya S, Kawakami M, Rappoport L, et al. 2007. Anti-catabolic effect of OP-1 in chronically compressed intervertebral discs. J Orthop Res 25:517-530.
8. LeMaitre CL, Freemont AJ, Hoyland JA. 2005. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther 7:R732-R745.
9. Takegami K, Thonar EJ, An HS, et al. 2002. Osteogenic protein-1 enhances matrix replenishment by intervertebral disc cells previously exposed to interleukin-1. Spine 27:1318-1325.
10. Jimbo K, Park JS, Yokosuka K, et al. 2005. Positive feedback loop of IL-lbeta upregulating production of inflammatory mediators in human intervertebral disc cells in vitro. J Neurosurg Spine 2:589-595.
11. LeMaitre CL, Freemont AJ, Hoyland JA. 2004. Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc. J Pathol 204:47-54.
12. Kang JD, Georgescu HI, McIntyre-Larkin L, et al. 1996. Herniated lumbar intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, IL-6, and P GE2. Spine 21:271-277.
13. Handa T, Ishihara H, Ohshima H, et al. 1997. Effects of hydrostatic pressure on matrix synthesis and matrix metal-loproteinase production in the human lumbar intervertebral disc. Spine 22:1085-1091.
14. Kanemoto M, Hukuda S, Komiya Y, et al. 1996. Immunohis-tochemical study of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in human intervertebral discs. Spine 21:1-8.
15. Anderson DG, Izzo MW, Hall DJ, et al. 2002. Comparative gene expression profiling of normal and degenerative discs. Spine 27:1291-1296.
16. Kang JD, Stefanovic-Racic M, McIntyre LA, et al. 1997. Toward a biochemical understanding of human intervertebral disc degeneration and herniation. Spine 22:1065-1073.
17. van der Kraan PM, van den Berg WB. 2000. Anabolic and destructive mediators in osteoarthritis. Curr Opin Clin Nutr Metab Care 3:205-211.
18. Studer RK, Aboka AM, Gilbertson LG, et al. 2007. p38 MAPK inhibition in nucleus pulposus cells: a potential target for treating intervertebral disc degeneration. Spine 32:2827-2833.
19. Studer RK, Bergman R, Stubbs T, et al. 2003. Chondrocyte response to growth factors is modulated by p38 MAPK inhibition. Arthritis Res Ther 6:R56-R64.
20. Studer RK, Chu CR. 2005. p38 MAPK and COX2 inhibition modulate human chondrocyte response to TGF-beta. J Orthop Res 23:454-461.
21. Rannou F, Lee T-S, Zhou R-H, et al. 2004. Intervertebral disc degeneration: the role of the mitochondrial pathway in annulus fibrosus cell apoptosis induced by overload. Am J Pathol 164:915-924.
22. Lali FV, Hunt AD, Turner SJ, et al. 2000. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phos-phorylation, and retinoblastoma hyperphosphorylation in IL-2 stimulated T cells independently of p38 mitogenactivated protein kinase. J Biol Chem 275:7395-7402.
23. Lee GM, Tioran ME, Jansen M, et al. 2002. Development of selective tolerance to IL-lbeta by human chondrocytes in vitro. J Cell Physiol 192:113-124.
24. Sztrolovics R, Grover J, Cs-Szabo G, et al. 2002. The characterization of versican and its message in human articular cartilage and intervertebral disc. J Orthop Res 20:257-266.
25. CsSzabo G, Ragasa-San Juan D, Turumella V, et al. 2002. Changes in mRNA and protein levels of proteoglycans of the annulus fibrosus and nucleus pulposus during intervertebral disc degeneration. Spine 27:2212-2219.
26. Tsai T-T, Guttapalli A, Oguz E, et al. 2007. Fibroblast growth factor-2 maintains the differentiation potential of nucleus pulposus cells in vitro. Spine 32:495-502.
27. Yang BL, Yang BB, Erwin M, et al. 2003. Versican G3 domain enhances cellular adhesion and proliferation of bovine intervertebral disc cells cultured in vitro. Life Sci 73:3399-3413.
28. Hayes AJ, Benjamin M, Ralphs JR. 2001. Extracellular matix in development of the intervertebral disc. Matrix Biol 20:107-121.
29. Melrose J, Ghosh P, Taylor TKF. 2001. A comparative analysis of the differential spatial and temporal distributions of the large (aggrecan, versican) and small (decorin, biglycan, fibromodulin) proteoglycans of the intervertebral disc. J Anat 198:3-15.
30. Studer RK, Georgescu HI, Miller LA, et al. 1999. Inhibition of TGF-β production by NO-treated chondrocytes. Arthritis Rheum 42:248-257.
31. Andriamanalijaona R, Felisaz H, Kim SJ, et al. 2003. Mediation of IL-1β-induced TGF-β1 expression by AP-4 transcription factor in primary cultures of bovine articular chondrocytes; possible cooperation with AP-1. Arthritis Rheum 48:1569-1581.
32. Walsh AJL, Bradford DS, Lotz JC. 2004. In vivo growth factor treatment of degenerated intervertebral discs. Spine 29:156-163.
33. Nishida K, Rang JD, Gilbertson LG, et al. 1999. Modulation of the biologic activity of the rabbit intervertebral disc by gene therapy; an in vivo study of adenovirus-mediated transfer of the human transforming growth factor beta 1 encoding gene. Spine 24:2419-2425.
34. Sive JI, Baird P, Jeziorsk M, et al. 2002. Expression of chondrocyte markers by cells of normal and degenerate intervertebral discs. Mol Pathol 55:91-97.
35. Zhang Y, An HS, Thonar EJ, et al. 2006. Comparative effects of bone morphogenetic proteins and sox9 overexpression on extracellular matrix metabolism of bovine nucleus pulposus cells. Spine 31:2173-2179.
36. Badger AM, Griswold DE, Kapadia R, et al. 2000. Disease-modifying activity of SB 242235,a selective p38 MAPK inhibitor, on IL-1 treated bovine and human cartilage/ chondrocyte cultures. Osteoarthritis Cartilage 8:434-443.
37. Miyamoto H, Doita M, Nishida K, et al. 2006. Effects of cyclic mechanical stress on the production of inflammatory agents by nucleus pulposus and anulus fibrosus derived cells in vitro. Spine 31:4-9.
38. Goldring MB, Berenbaum R. 2004. The regulation of chondrocyte function by proinflammatory mediators. Clin Orthop Relat Res 427S:S37-S46.
39. Burke JG, Watson RW, McCormack D, et al. 2002. Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. J Bone Joint Surg [Br] 84:196-201.
40. Li H, Zou X, Baatrup A, et al. 2005. Cytokine profiles in conditioned media from cultured human intervertebral disc tissue. Acta Orthop 76:115-121.
41. Rousseau M-AA, Ulrich JA, Bass EC, et al. 2007. Stab incision for inducing intervertebral disc degeneration in the rat. Spine 32:17-24.
42. Wong PKK, Campbell IK, Egan PJ, et al. 2003. The role of the IL-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum 48:1177-1189.
43. Legendre F, Dudhia J, Pujol J-P, et al. 2003. JAK/STAT but not ERK1/ERK2 pathway mediated IL-6/soluble IL-6R down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. J Biol Chem 278: 2903-2912.
44. Legendre F, Bogdanowicz P, Boumediene K, et al. 2005. Role of IL-6/IL-6R-induced signal tranducers and activators of transcription and MAPK/ERK in upregulation of matrix metalloproteinase and ADAMTS gene expression in articular chondrocytes. J Rheumatol 32:1307-1316.
45. Flannery CR, Little CB, Hughes CE, et al. 2000. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol 19:549-553.
46. Studer RK, Ondeck C, Georgescu H, et al. 2007. IL-6 effects on nucleus pulposus cells: implications for treatment of intervertebral disc degeneration. Transactions of the Orthopaedic Research Society 32:1094, ORS, Rosemont, IL.
47. Dayer J-M, Molnarfi N, Burger D. 2005. From cellular receptors to transduction-transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation? Expert Opin Biol Ther 5 (Suppl 1):S83-S96.
48. Tas SW, Remans PH, Reedquist KA, et al. 2005. Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. Curr Pharm Des 11:581-611.